Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis

Multiple sclerosis (MS) remains one of the most challenging neurological diseases, affecting more than 2.8 million people worldwide and approximately 1 million in the USA. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented therapeutic candidate designed to target demyelination and provide neuroprotection in multiple sclerosis to address loss of mobility and function.

Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body. The company recently announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated. This milestone was followed in April 2026 by the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, marking a significant step toward clinical development for MS patients.

Multiple sclerosis is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include vision problems, muscle weakness, and coordination difficulties. Quantum BioPharma’s approach aims to directly address the myelin damage and neurodegeneration that current immune-modulating therapies may not fully target. The company’s progress with LUCID-MS offers hope for a new class of treatments that could slow or halt disease progression and improve quality of life for the millions affected by MS. For more details, Read More on BiomedWire.